Aim: To investigate the association between structured self-monitoring of blood glucose (SMBG) and diabetes self-efficacy in Chinese patients.
| INTRODUCTION
Self-efficacy is defined as the confidence or belief of a patient in understanding and managing a disease and may greatly influence the patient's knowledge about the disease and the importance of adherence to treatment, especially for chronic diseases such as diabetes.
Therefore, an important part of diabetes management is improving patients' self-efficacy and thereby increasing their adherence to treatment. 1 Comprehensive management of diabetes includes diet, exercise, blood glucose (BG) monitoring, antidiabetic drugs, and education. Self-monitoring of BG (SMBG) is a basic method used to monitor BG, which is particularly important for the management of diabetes. 2 However, the current prevalence of SMBG is rather low.
Only 18.98% of patients are willing to perform SMBG according to the guidelines, and 35.36% of patients have never performed SMBG. 3 Therefore, increasing awareness in China of the importance of SMBG is essential. In addition, a practical and economically effective SMBG protocol is necessary for diabetes patients. Structured SMBG has been proven to be able to increase the frequency of SMBG and significantly improve glycaemic control. 4 We previously reported in a single-centre, Yun Shen and Wei Zhu equal contributors.
randomized controlled trial that structured SMBG was effective for glycaemic control in patients receiving insulin treatment and in young and middle-aged patients without insulin treatment with no strict deterioration of quality of life. 5 We also recorded data on the changes in diabetes self-efficacy before and at the end of the same trial as the secondary outcome. No study has reported the effect of structured SMBG on diabetes self-efficacy in China. Therefore, we aimed to investigate the association between structured SMBG and diabetes self-efficacy in Chinese patients in this analysis. 
| METHODS

| Trial design
| Study patients
Eligible subjects were adult patients with both type 1 and type 2 diabetes (≥18 years old) with a definite diagnosis of diabetes and glycated haemoglobin A 1c (HbA 1c ) ≥ 8% measured within the month prior to enrolment, were not performing SMBG on a regular (daily) basis within the 3 months prior to enrolment, were willing and able to use a BG metre to perform daily SMBG, were willing and able to complete the participant questionnaires, and were willing and able to visit a physician at months 3 and 6.
Diabetes was diagnosed and confirmed in patients with classic symptoms of hyperglycaemia based on either fasting plasma glucose Patients were excluded if they had any retinopathy that required photocoagulation or retinal surgery in the 6 months prior to enrolment or that potentially required photocoagulation or retinal surgery during the study, any clinically significant condition requiring hospitalization in the last 2 months prior to enrolment or that potentially required hospitalization (eg, elective surgery) during the study, or any clinically significant psychosis or cognitive impairment; they were also excluded if they were unlikely to comply with or complete the study or were pregnant, lactating, or planning to become pregnant during the study period.
The study protocol was approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People's Hospital. All patients provided written informed consent.
| Interventions
The patients in the intervention group were instructed on the use of the BG metre and were advised to perform daily SMBG according to the instructions (before and after one meal per day with a rotation of testing among meals [ie, paired testing for breakfast (day 1), then lunch (day 2), then dinner (day 3), and possibly supper if it was substantial (day 4), followed by repeating the cycle]). A professional health-care team provided a diabetes education programme to the patients in both the intervention and control groups, which included the glycaemic goal, types of antihyperglycaemic drugs, and guidance for a healthy lifestyle. The patients in the control group were also instructed on the use of SMBG but were not provided the structured regimen. The patients were prescribed SMBG at each visit.
| Sample size
We aimed to detect a difference of at least 0.5% in changes from 
| Randomization, treatment, and follow-up
The patients were randomly assigned to the intervention and control groups in a 1:1 ratio after a 3-month screening period. The randomization sequence was generated by the institutional staff and was concealed from the physicians during follow-up. Anthropometric and clinical data were collected from the patients at baseline and at the third and sixth months after the intervention; these data included the body mass index, HbA 1c , FPG, 2hPG, and self-efficacy scores.
The data were collected from medical records, laboratory measurements, and questionnaires. Two-hour postprandial glucose at baseline and at every visit was measured after a 100-g carbohydrate meal.
The follow-up lasted 6 months. During the follow-up, the patients in the intervention group were instructed on how to use the BG metre. The physicians were directed to evaluate the application 
| Anthropometric and laboratory measurements
Height and weight were measured for all patients. The body mass index was calculated as the weight in kilograms divided by the square of the height in metres. Fasting plasma glucose, 2hPG, and HbA 1c were measured at baseline and at the third and sixth months. Plasma glucose was measured via the glucose oxidase method, and HbA 1c was measured via high-performance liquid chromatography. The laboratory was certified by the National Glycohemoglobin Standardization Program.
| Outcomes
The primary outcome has been described and reported previously. In this analysis, diabetes self-efficacy scale (DSES) scores 9, 10 were assessed throughout the trial, including 18 items on topics such as diabetes management, SMBG, diet, and exercise. The scores for each item ranged from 1 to 6, and the total score ranged from 18 to 108. Higher scores indicated poorer self-efficacy. The prespecified outcome in this analysis was changes in the DSES scores from baseline to the third and sixth months.
| Blinding
No blinding was performed in this trial. Only the analyst who assessed the outcomes was blind to this trial.
| Statistical analysis
The analysis was performed according to the intention-to-treat principle. The data are reported as the mean ± SD unless otherwise stated.
One-way ANOVA was used to analyse differences from baseline to Table 1 . In the patients with and without insulin treatment, we found that patients with higher DSES scores (ie, poorer self-efficacy) had higher baseline HbA 1c levels (P < .001). In addition, in patients with and without insulin treatment, fewer patients had diabetic retinopathy (DR) in the higher DSES scores group (P < .001). In the patients without insulin treatment, patients with higher DSES scores had higher FPG levels (P < .001).
| Association between diabetes self-efficacy and glycaemic control at baseline
To evaluate the independent association between HbA 1c and the DSES scores at baseline, we performed a stepwise regression analysis with HbA 1c as the dependent variable ( Table 2) . We found that after adjusting for confounding factors, including gender, age, insulin treatment status, diabetic complications, and disease duration, the DSES scores emerged as an independent influential factor for HbA 1c
(β = 0.064, P < .001).
| Observed outcomes
We collected the DSES scores of the patients at baseline and at the third and sixth months. We used a multivariate generalized estimating equation model to analyse changes in the DSES scores with adjustments for confounding factors (Table 3 ). In the intervention group, all comparisons of DSES scores between baseline and the third month, the third month and the sixth month, and baseline and the sixth month were significant (Wald β = 7.882, P < .001; Wald β = 3.130, P = .003;
Wald β = 7.879, P < .001, respectively), which indicated that the DSES scores tended to decrease (ie, the diabetes self-efficacy improved) during the follow-up period. However, in the control group, all comparisons were nonsignificant, indicating the sustained contribution of structured SMBG to diabetes self-efficacy.
| Changes in the DSES scores and glycaemic control
We generated a figure including both changes in the DSES scores and glycaemic control (Figure 2 ). Glycaemic control significantly improved in both the intervention and control groups at the third month (both P < .05). The patients in the intervention group benefited more in terms of glycaemic control than those in the control group (P < .05). In the intervention group, the sustained improvement of the DSES scores maintained improvement in glycaemic control until the sixth month. In the control group, glycaemic control tended to deteriorate in the sixth month without the support of improved DSES scores (P = .056).
| DISCUSSION
This study is a subgroup analysis of a clinical trial investigating structured SMBG and mainly illustrates the associations among structured SMBG, glycaemic control, and diabetes self-efficacy. We found that The protocol for structured SMBG was designed based on a preexisting SMBG regimen in which patients performed glucose testing before and after 1 meal per day, which might help promote understanding of the effects of diet on glycaemic control and enable effective implementation of dietary and treatment improvements. In previous studies, structured SMBG was shown to be effective for glycaemic control in type 2 diabetes patients treated with insulin. 11 In a clinical trial with type 2 diabetes patients without insulin treatment, structured SMBG reduced the HbA 1c level by 0.32%. 12 Mannucci E et al performed a meta-analysis of the effect of structured SMBG on type 2 diabetes The data are expressed as the mean ± SD or the median. Statistics for categorical variables are expressed as the number of patients (percentage of patients).
*P < .05 in both insulin treated and noninsulin treated groups; subgroup with baseline DSES scores lower than median vs greater than median. patients without insulin treatment and found that structured SMBG effectively reduced the HbA 1c level. 13 However, no study has reported the sustained contribution of structured SMBG to diabetes self-efficacy.
Our study is the first to find that structured SMBG effectively improved In addition, nearly 35.36% of patients reported that they had never performed SMBG. 3 The most likely reason is that the BG metre and the assorted test strips are not covered by most health-care insurance organizations in China, which will place a large financial burden on diabetes patients. The design of this trial fully considered confounding factors, including gender, age, and chronic diabetes complications, which were all nonsignificant between the intervention and control groups at baseline except for the duration of diabetes. Our results are also applicable to all therapies rather than insulin alone. Structured SMBG combined with diabetes education can effectively benefit diabetes self-efficacy and should be promoted in China. This approach is also a more proper regimen to meet the needs of clinical practice without placing a financial burden on the patients.
In this trial, diabetes self-efficacy was sustainably improved by structured SMBG, resulting in maintenance of glycaemic control until the end of the trial. In a previous study by Shao Y et al, improvement of self-efficacy positively contributed to a decline in the HbA1c level through social supportive education. 14 This trial has some limitations. First, the patients were only separated into insulin-treated and noninsulin-treated groups in this trial, and thus, we could not rule out the impact of other specific treatments on glycaemic control. Second, the follow-up period was short and might not have been sufficient for evaluation of the long-term impact of structured SMBG on glycaemic control and diabetes self-efficacy. Additionally, the rate of hypoglycaemic events was not recorded during the follow-up period. Finally, data on diet, exercise, or other lifestyle factors were not available in our study, which might introduce bias into the improvement of glycaemic control.
In conclusion, structured SMBG effectively and sustainably improved diabetes self-efficacy in Chinese diabetes patients, which might help maintain improved glycaemic control.
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